Abstract: Metformin as the first-line drugs, play an important role in the treatment of diabetes. Metabolic syndrome（MS） is a pathological condition of abnormal aggregation of multiple metabolite resulting. The long-term adverse outcomes were payed more and more attention by people. The study found, MS is recognized risk factor of endometrial adenocarcinoma, there may be a common pathophysiological basis of insulin resistance. Metformin reduces insulin resistance, regulates the level of cytokines and exerts anti-tumor stem cell function, it is a potent inhibitor of metabolic syndrome and endometrial adenocarcinoma.

Key words: Metformin, Metabolic syndrome X, Endometrial neoplasms, Therapy